Grupo Biotoscana has launched Basilea’s hospital antibiotic Zevtera (ceftobiprole) in Argentina, Basilea Pharmaceutica said Tuesday.
This is Basilea’s first launch of the brand in the Latin America region and also the first launch of Zevtera in any country outside Europe, David Veitch, Chief Commercial Officer, said: “We are looking forward to GBT making our broad-spectrum anti-MRSA antibiotic available to patients in Argentina and subsequently in other Latin American countries following regulatory approval.”
Zevtera is approved in Argentina for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP), Basilea said.
The agreement that Basilea entered for Zevtera and the antifungal Cresemba (isavuconazole) with GBT was concluded in September 2016 and it covers 19 countries in Latin America, including Argentina. Basilea got CHF11 million upfront payment from GBT.
As Basilea has pointed out, it supplies GBT with Zevtera at a transfer price and is eligible to receive further regulatory and sales milestone payments.